High rate of spontaneous disease regression in men with high-grade pre-cancerous anal lesions

Michael Carter
Published: 10 June 2013

High-grade pre-cancerous anal lesions are more likely to regress than progress, according to Australian research published in the online edition of AIDS. The study involved 574 men, three-quarters of whom were HIV positive. Only 1% of patients progressed to anal cancer, compared to a regression rate of 24%.

“Our data provide reassurance that high-grade ASILs [anal squamous intraepithelial lesions] diagnosed at any one point are much more likely to spontaneously regress than progress to cancer,” write the authors. “Not all patients with high-grade ASILs warrant treatment.”

Incidence of anal cancer has increased among HIV-positive people, with rates highest among men who have sex with men. Anal cancer is caused by persistent infection with high-risk strains of human papillomavirus (HPV) and is preceded by a pre-cancerous phase of cell changes called high-grade ASIL. This is divided into grade 2 or grade 3 anal intraepithelial neoplasia (AIN2, AIN3). These diagnoses are often combined together as high-grade anal intraepithelial neoplasia (HGAIN).

Investigators at St Vincent’s Hospital, Sydney, were concerned that relatively little is known about rates of disease progression and regression in people with HGAIN. However, they noted that high rates of spontaneous disease regression have been observed in women with cervical intraepithelial neoplasia. They hypothesised that this would also be the case with high-grade ASILs. The investigators also hypothesised that the likelihood of disease progression to HGAIN would be related to HIV infection status and CD4 cell count.

They therefore designed a retrospective study involving 570 men who had undergone an anal Pap smear or high-resolution anoscopy between 2004 and 2011. Three-quarters of these men were HIV positive. These HIV-positive participants had a median CD4 cell count of 500 cells/mm3 and 84% had an undetectable viral load.

Participants were followed for a median of one year.

A total of 152 people were eligible for inclusion in the analysis of disease progression. Overall, 19 individuals (12.5%) developed incident HGAIN over 256 person-years of follow-up. The incidence of progression to HGAIN was 7.4 per 100 person-years. This did not differ significantly between the HIV-positive and HIV-negative men.

Incidence of progression to AIN3 was 8.1 per 100 person-years. Incidence differed according to HIV status and was significantly higher among the HIV-positive participants (13.1 vs 4.5 per 100 person-years).  Having an abnormal baseline diagnosis (AIN1, AIN2) was associated with disease progression (p < 0.001). Among the HIV-positive men, a nadir CD4 cell count below 200 cells/mm3 was a risk factor for progression to AIN3 (HR = 4.66; 95% CI, 1.65-13.11).

There were four new cases of anal cancer during follow-up. Two people had HGAIN prior to their diagnosis with anal cancer. The incidence rate of progression to anal cancer among participants with HGAIN was 1.2 per 100 person-years.

The authors note that both incident anal cancers occurred in HIV-positive people with a nadir CD4 cell count below 200 cells/mm3. “Our data support current guidelines that recommend any abnormality on anal cytology warrants further investigation with HRA [high-resolution anoscopy], as two of four incident anal cancers had only low grade cytology a short time before the diagnosis of cancer,” observe the authors.

There was a high rate of spontaneous disease regression from HGAIN among the 101 people eligible for inclusion in this analysis. Overall, 24% of participants experienced spontaneous improvement in their disease, a regression incidence of 24 per 100 person-years. Biopsy showed that most of these people (71%) regressed to AIN1, the other 29% being totally free of any disease.  

Spontaneous regression from AIN3 was observed in 26 (47%) of the 55 participants included in this analysis. Overall, these people contributed 38 person-years of follow-up, and the incidence of regression was 69 per 100 person-years. Rates of regression were similar between the HIV-positive and HIV-negative men.

“High-grade ASILs frequently spontaneously regressed,” conclude the authors. “Prospective studies to delineate risk factors and biomarkers that predict those at highest risk of progression to cancer are needed so that intervention can be targeted, and avoided in those for whom it is unlikely to be of value.”


Tong WWY et al. Progression to an spontaneous regression of high-grade anal squamous intraepithelial lesions in HIV-infected and uninfected men. AIDS 23, online edition, doi: 10.1097/QAD.0b013e3283633111, 2013.

Related news selected from other sources

More editors' picks on cancer >
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.